Novartis beats sales expectations for Genmab-developed Kesimpta
Swiss Novartis has surpassed projections for multiple sclerosis treatment Kesimpta, based on Genmab’s antibody ofatumumab, in the second quarter.
by marketwire translated by daniel pedersen
Swiss pharmaceutical giant Novartis has exceeded analysts’ expectations for second-quarter sales of Kesimpta, a treatment for multiple sclerosis developed by Danish biotech firm Genmab, which receives 10% of sales in royalty payments under an existing licensing agreement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
